Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced positive results from two key clinical trials for its investigational drug, VEGF Trap-Eye (aflibercept ophthalmic solution). The press release, filed on December 20, 2010, detailed positive outcomes from a Phase 3 study in Central Retinal Vein Occlusion (CRVO) and a Phase 2 study in Diabetic Macular Edema (DME). These trial results are significant for investors as they represent advancements in the development of potential treatments for serious retinal conditions, potentially expanding Regeneron's product pipeline and future revenue streams. The drug was generally well-tolerated in both studies, with specific details provided regarding serious adverse events, indicating a favorable safety profile thus far.
Key Highlights
- 1Positive results announced for VEGF Trap-Eye in Phase 3 study for Central Retinal Vein Occlusion (CRVO).
- 2Positive results announced for VEGF Trap-Eye in Phase 2 study for Diabetic Macular Edema (DME).
- 3VEGF Trap-Eye demonstrated a generally well-tolerated safety profile in both studies.
- 4No ocular drug-related serious adverse events reported in the CRVO Phase 3 study.
- 5One non-ocular drug-related serious adverse event reported in the second six months of the CRVO Phase 3 study.
- 6The company is advancing its pipeline with promising late-stage trial data.
- 7These results could lead to new treatment options for significant ophthalmic diseases.